ArticleCancer communications (London, England)2025

Stereotactic body radiotherapy plus cadonilimab (PD-1/CTLA-4 bispecific antibody) as third-line or beyond therapy for refractory solid tumors: A phase 1b study.

Yao Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.